Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy

Bibliographic Details
Main Authors:	Mi Zhou, Xiaoming Liu, Jiawen Zhang, Carson A Wills, Longgui Chen, Yuanjun Zhao, Jeffrey M Sundstrom, Todd Schell, Vladimir S Spiegelman, Megan M Young, Hong-Gang Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-04-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/4/e004399.full

Similar Items

Chemotherapy-induced small extracellular vesicles prime the pre-metastatic niche to accelerate neuroblastoma metastasis
by: Carson A. Wills, et al.
Published: (2024-07-01)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
by: Godfrey Chi-Fung Chan, et al.
Published: (2022-02-01)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
by: Miranda P Dierselhuis, et al.
Published: (2023-07-01)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
by: Judith E Karp, et al.
Published: (2008-09-01)

Identification of Contactin-1 as a Potential Biomarker and Therapeutic Target in Neuroblastoma
by: Christa N. Grant, et al.
Published: (2024-11-01)

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
by: Irina V. Kholodenko, et al.
Published: (2018-01-01)

Prospects of anti-GD2 immunotherapy for retinoblastoma
by: Xinlong Zhang, et al.
Published: (2024-11-01)

Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics
by: Mayura R. Dhamdhere, et al.
Published: (2024-04-01)

Neuroblastoma: an ongoing cold front for cancer immunotherapy
by: Paul T Kennedy, et al.
Published: (2023-11-01)

Immunotherapy for neuroblastoma using mRNA vaccines
by: Tanvir Ahmed
Published: (2022-07-01)

Biology of GD2 ganglioside: implications for cancer immunotherapy
by: Pierre Machy, et al.
Published: (2023-08-01)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
by: Adeiye A. Pilgrim, et al.
Published: (2023-12-01)

Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
by: Christin Eger, et al.
Published: (2016-01-01)

Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy
by: Witida Laopajon, et al.
Published: (2023-12-01)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
by: Jaume Mora, et al.
Published: (2020-10-01)

Characteristics of the immune environment in prostate cancer as an adjunct to immunotherapy
by: Xinhai Yin, et al.
Published: (2024-07-01)

Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy
by: Linda Davidson, et al.
Published: (2018-01-01)

Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy.
by: Bhagwant Kaur Sekhon, et al.
Published: (2016-01-01)

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia
by: Lancet Jeffrey E, et al.
Published: (2004-08-01)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
by: Jianping Sun, et al.
Published: (2020-10-01)

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
by: Julien Fleurence, et al.
Published: (2017-01-01)

The biological role and immunotherapy of gangliosides and GD3 synthase in cancers
by: Shangqi Cao, et al.
Published: (2023-02-01)

Hopes on immunotherapy targeting B7-H3 in neuroblastoma
by: Rafael Pulido, et al.
Published: (2023-01-01)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
by: Kevin O. McNerney, et al.
Published: (2020-05-01)

Prospect of extracellular vesicles in tumor immunotherapy
by: Wenbo Xia, et al.
Published: (2025-02-01)

Magnetite nanoparticles: an emerging adjunctive tool for the improvement of cancer immunotherapy
by: Phoomipat Jungcharoen, et al.
Published: (2024-04-01)

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
by: Srinivasa Reddy Bonam, et al.
Published: (2020-05-01)

Immunotherapy for sarcomas: new frontiers and unveiled opportunities
by: Carolyn Nessim, et al.
Published: (2021-02-01)

Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy
by: Jian Cheng, et al.
Published: (2025-01-01)

The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors
by: Thanh-Phuong Le, et al.
Published: (2017-11-01)

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells
by: Husheng Ding, et al.
Published: (2014-01-01)

Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy
by: Scott Strum, et al.
Published: (2024-12-01)

Extracellular Vesicle-Based Strategies for Tumor Immunotherapy
by: Luksika Jiramonai, et al.
Published: (2025-02-01)

Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy
by: Xiaoyu An, et al.
Published: (2023-12-01)

Bacterial extracellular vesicle applications in cancer immunotherapy
by: Kanika Suri, et al.
Published: (2023-04-01)

Cell-derived vesicles for delivery of cancer immunotherapy
by: Jialu Xu, et al.
Published: (2021-02-01)

GD2 targeting CAR T cells for neuroblastoma
by: John Anderson, et al.
Published: (2024-12-01)

Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Published: (2022-04-01)

Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy
by: Karen Slattery, et al.
Published: (2022-10-01)